Heron Therapeutics, Inc. HRTX
0.30 USD -0.01 (-3.35%)
As ofNov 16, 2026, 2:07 PM EST
0.299 Day range 0.3297
0.26 52-week range 1.58
- YTD
- -76.92%
- 1 year
- -72.72%
News
benzinga.com Deal Dispatch: Morgan Stanley Buys Vinyl Equity, Fox Completes Roku Acquisition, Children's Place Files for Chapter 11 Major M&A deals this week include: CorMedix buys Heron for $145M and Craveworthy Brands buys New England Authentic Eats.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 19.6% to $9.6 during Friday's pre-market session. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3…
zacks.com CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.
seekingalpha.com Heron Therapeutics, Inc. (HRTX) M&A Call Transcript Heron Therapeutics, Inc. ( HRTX ) M&A Call November 9, 2026 4:30 PM EST Company Participants Joseph Todisco - CEO & Chairman of the Board of Directors Conference Call Participants Daniel Ferry -…
benzinga.com CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal CorMedix Therapeutics (NASDAQ:CRMD) on Monday said it will acquire substantially all assets and assume certain liabilities of Heron Therapeutics, Inc. (NASDAQ:HRTX) in an upfront transaction valued…
benzinga.com CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal CorMedix acquires Heron Therapeutics assets for $222.6 million upfront, adding four commercial hospital therapies to expand its acute care reach.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
zacks.com Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.05 per share a year ago.
globenewswire.com Heron Therapeutics Announces Third Quarter 2026 Financial Results CARY, N.C., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company focused on improving the lives of patients…benzinga.com Heron Therapeutics Q3 EPS $(0.03), Inline, Sales $35.250M Miss $37.500M Estimate Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(0.04) per share from the same…
benzinga.com CorMedix To Acquire Heron Therapeutics Assets For $145M Cash, Stock, And Potential Earn-Out Payments Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platformUpfront consideration consisting of $145 million…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers MaxCyte (NASDAQ:MXCT) stock increased by 21.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $130.0 million. Vir Biotechnology (NASDAQ:VIR)…
globenewswire.com CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care Adds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…
